Range Cancer Therapeutics ETF is a ETF series of ETF Series Solutions (series S000050740). Net assets $8.9M as of 2025-02-28. Index fund.
Showing 15 of 76 holdings by value.
| Holding | Ticker | Value | % of fund |
|---|---|---|---|
| Recursion Pharmaceuticals Inc | — | $358K | 401.29% |
| Precigen Inc | — | $272K | 305.02% |
| Compass Therapeutics Inc | — | $267K | 298.95% |
| Genelux Corp | — | $259K | 290.10% |
| SpringWorks Therapeutics Inc | — | $256K | 286.33% |
| Exelixis Inc | — | $222K | 248.31% |
| Ginkgo Bioworks Holdings Inc | — | $208K | 233.16% |
| Replimune Group Inc | — | $191K | 213.70% |
| Bristol-Myers Squibb Co | — | $188K | 210.28% |
| Schrodinger Inc/United States | — | $177K | 198.03% |
| Blueprint Medicines Corp | — | $176K | 197.29% |
| Zymeworks Inc | — | $169K | 188.82% |
| Vor BioPharma Inc | — | $168K | 188.49% |
| HUTCHMED China Ltd | — | $157K | 175.55% |
| Innate Pharma SA | — | $154K | 172.61% |
| Report date | Net assets |
|---|---|
| 2025-02-28 | $8.9M |
| 2024-11-30 | $11.9M |
| 2024-08-31 | $13.3M |
| 2024-05-31 | $16.5M |
| 2024-02-29 | $19.4M |
| 2023-11-30 | $11.3M |
| 2023-08-31 | $9.6M |
| 2023-05-31 | $13.3M |